Search research articles
Contact Us
Filters
Showing results (201-210 of 328) with videos related to
Page
of 33
Sort By:
Blood Advances
|
June 30, 2023
Prognostic factors for adult patients with Burkitt lymphoma treated with dose-adjusted EPOCH-R
Rahul Lakhotia, Kieron Dunleavy, Jeremy S Abramson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 7, 2012
Results of a phase 1 study of AME-133v (LY2469298), an Fc-engineered humanized monoclonal anti-CD20 antibody, in FcγRIIIa-genotyped patients with previously treated follicular lymphoma
Andres Forero-Torres, Sven de Vos, Brad L Pohlman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 20, 2005
Response assessment of aggressive non-Hodgkin's lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography
Malik E Juweid, Gregory A Wiseman, Julie M Vose, et al.
American Journal of Hematology
|
June 22, 2012
Germline variation in complement genes and event-free survival in follicular and diffuse large B-cell lymphoma
Bridget Charbonneau, Matthew J Maurer, Zachary S Fredericksen, et al.
Medrxiv : the Preprint Server for Health Sciences
|
December 16, 2024
Primary Central Nervous System Lymphoma Tumor Biopsies Show Heterogeneity in Gene Expression Profiles, Genetic Subtypes, and in vitro Drug Sensitivity to Kinase Inhibitors
Yuan Xiao Zhu, Jasper Ch Wong, Talal Hilal, et al.
American Journal of Hematology
|
March 27, 2026
High Soluble Tumor Necrosis Factor Receptor 2 in Serum Is Associated With Inferior Overall Survival Across Major Lymphoma Subtypes
Arushi Khurana, Hikaru Hayashi, Bethany Thach, et al.
British Journal of Haematology
|
September 30, 2017
Event-free survival at 24 months captures central nervous system relapse of systemic diffuse large B-cell lymphoma in the immunochemotherapy era
Gita Thanarajasingam, Matthew J Maurer, Umar Farooq, et al.
Blood Advances
|
January 8, 2025
The A-HIPI prediction model in advanced-stage Hodgkin lymphoma: identification of risk groups and creation of an online tool
Matthew J Maurer, Susan K Parsons, Jenica N Upshaw, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 31, 2013
Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: a report from the University of Iowa/MayoClinic Specialized Program of Research Excellence Molecular Epidemiology Resource
Brian K Link, Matthew J Maurer, Grzegorz S Nowakowski, et al.
Blood Cancer Journal
|
November 10, 2020
Somatic copy number gains in MYC, BCL2, and BCL6 identifies a subset of aggressive alternative-DH/TH DLBCL patients
Jordan E Krull, Kerstin Wenzl, Keenan T Hartert, et al.
Page
of 33
Search research articles
Search
Showing results (201-210 of 328) with videos related to
Sort By:
Page
of 33
Blood Advances
|
June 30, 2023
Prognostic factors for adult patients with Burkitt lymphoma treated with dose-adjusted EPOCH-R
Rahul Lakhotia, Kieron Dunleavy, Jeremy S Abramson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 7, 2012
Results of a phase 1 study of AME-133v (LY2469298), an Fc-engineered humanized monoclonal anti-CD20 antibody, in FcγRIIIa-genotyped patients with previously treated follicular lymphoma
Andres Forero-Torres, Sven de Vos, Brad L Pohlman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 20, 2005
Response assessment of aggressive non-Hodgkin's lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography
Malik E Juweid, Gregory A Wiseman, Julie M Vose, et al.
American Journal of Hematology
|
June 22, 2012
Germline variation in complement genes and event-free survival in follicular and diffuse large B-cell lymphoma
Bridget Charbonneau, Matthew J Maurer, Zachary S Fredericksen, et al.
Medrxiv : the Preprint Server for Health Sciences
|
December 16, 2024
Primary Central Nervous System Lymphoma Tumor Biopsies Show Heterogeneity in Gene Expression Profiles, Genetic Subtypes, and in vitro Drug Sensitivity to Kinase Inhibitors
Yuan Xiao Zhu, Jasper Ch Wong, Talal Hilal, et al.
American Journal of Hematology
|
March 27, 2026
High Soluble Tumor Necrosis Factor Receptor 2 in Serum Is Associated With Inferior Overall Survival Across Major Lymphoma Subtypes
Arushi Khurana, Hikaru Hayashi, Bethany Thach, et al.
British Journal of Haematology
|
September 30, 2017
Event-free survival at 24 months captures central nervous system relapse of systemic diffuse large B-cell lymphoma in the immunochemotherapy era
Gita Thanarajasingam, Matthew J Maurer, Umar Farooq, et al.
Blood Advances
|
January 8, 2025
The A-HIPI prediction model in advanced-stage Hodgkin lymphoma: identification of risk groups and creation of an online tool
Matthew J Maurer, Susan K Parsons, Jenica N Upshaw, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 31, 2013
Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: a report from the University of Iowa/MayoClinic Specialized Program of Research Excellence Molecular Epidemiology Resource
Brian K Link, Matthew J Maurer, Grzegorz S Nowakowski, et al.
Blood Cancer Journal
|
November 10, 2020
Somatic copy number gains in MYC, BCL2, and BCL6 identifies a subset of aggressive alternative-DH/TH DLBCL patients
Jordan E Krull, Kerstin Wenzl, Keenan T Hartert, et al.
Page
of 33